AR028424A1 - METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN - Google Patents

METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN

Info

Publication number
AR028424A1
AR028424A1 ARP010102149A ARP010102149A AR028424A1 AR 028424 A1 AR028424 A1 AR 028424A1 AR P010102149 A ARP010102149 A AR P010102149A AR P010102149 A ARP010102149 A AR P010102149A AR 028424 A1 AR028424 A1 AR 028424A1
Authority
AR
Argentina
Prior art keywords
regulating angiogenesis
ryk protein
ryk
protein
angiogenesis
Prior art date
Application number
ARP010102149A
Other languages
Spanish (es)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR028424A1 publication Critical patent/AR028424A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP010102149A 2000-05-10 2001-05-07 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN AR028424A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
AR028424A1 true AR028424A1 (en) 2003-05-07

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102149A AR028424A1 (en) 2000-05-10 2001-05-07 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN

Country Status (13)

Country Link
EP (1) EP1287121A2 (en)
JP (1) JP2004527206A (en)
AR (1) AR028424A1 (en)
AU (1) AU2001261343A1 (en)
CA (1) CA2408349A1 (en)
CO (1) CO5300464A1 (en)
DO (1) DOP2001000164A (en)
EC (1) ECSP014068A (en)
GT (1) GT200100079A (en)
PE (1) PE20011218A1 (en)
SV (1) SV2002000442A (en)
UY (1) UY26696A1 (en)
WO (1) WO2001085789A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050180959A1 (en) * 2002-02-06 2005-08-18 Karsten Eulenberg Kinases involved in the regulation of energy homeostasis
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
LT3170005T (en) 2014-07-18 2019-07-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
EP0804728A1 (en) * 1994-12-23 1997-11-05 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
CA2348835A1 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
UY26696A1 (en) 2001-12-28
CA2408349A1 (en) 2001-11-15
CO5300464A1 (en) 2003-07-31
GT200100079A (en) 2001-12-31
EP1287121A2 (en) 2003-03-05
SV2002000442A (en) 2002-07-03
DOP2001000164A (en) 2002-05-15
PE20011218A1 (en) 2002-02-01
WO2001085789A3 (en) 2002-05-16
ECSP014068A (en) 2002-02-25
AU2001261343A1 (en) 2001-11-20
JP2004527206A (en) 2004-09-09
WO2001085789A2 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
NO20025056L (en) Content creation / content acquisition system
AR027976A1 (en) HUMAN ANTIBODIES FOR CD154
FR2775183B1 (en) INTER-SPINOUS PROSTHESIS
ID23983A (en) AMINOTIAZOL INHIBITORS FOR CINCINES DEPENDING ON CYCLINES
CY2007029I1 (en) METHOD FOR THE PREPARATION OF SUBSTITUTED OCTANOYL-AMIDES
DE60133721D1 (en) BANDWIDTH CONTROL TECHNOLOGY FOR ONE LASER
ATE269324T1 (en) HYDROXYPHENYL-PIPERIDINE-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR PAIN CONTROL
DE60103427D1 (en) COMPLIANCE CONTROL METHOD
PT988861E (en) STABILIZED PROTEIN FORMULATIONS
AR028261A1 (en) TRICICLIC INHIBITORS OF PROTEIN QUINASA
DE60139754D1 (en) Quality Return procedures
AR028002A1 (en) METHODS FOR ANSAMITOCINE PRODUCTION
NO20001294D0 (en) Measures for thrust
DE60141570D1 (en) image editing
ATE289603T1 (en) CHINOLINYL-PIPERIDINE-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR PAIN CONTROL
PT1167260E (en) VITAMIN D3 DERIVATIVES
DE60113612D1 (en) Wiper control apparatus
DE60113610D1 (en) Wiper control apparatus
AR028424A1 (en) METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN
FI20002262A0 (en) A method for altering the structure of a protein
PT1171470E (en) ANTIBODIES FOR PLACENTARY PROTEIN 13
DE50107729D1 (en) control method
DE60129303D1 (en) An adjuster
ES1046497Y (en) SCURRIDOR FOR MOCHOS
ES1047195Y (en) DEVICE FOR MANUAL RETRACTATION.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal